X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

The continued imperative to protect U.S. innovation worldwide

By Chris Moore  |    April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...   Read More

Guest Post: Preserving clinical research sites during the coronavirus pandemic

By Guest Contributor  |    April 29, 2020
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Observing National Minority Health Month in the age of COVID-19

By Courtney Christian  |    April 24, 2020
Every April, National Minority Health Month is observed. The month is dedicated to continuing to raise awareness about health disparities affecting racial and ethnic minority groups. Each year,...   Read More

New report shows nearly 260 vaccines in development, including dozens for COVID-19

By Andrew Powaleny  |    April 23, 2020
Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases and, in many parts of the world, eliminating some of the most...   Read More

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

By Katie Koziara  |    April 20, 2020
Value-based programs between biopharmaceutical companies and pharmacy benefit manager Express Scripts saved $4.3 billion on medicines last year. Patients in these plans with innovative contracting...   Read More

Retail medicine spending to remain stable share of overall health care spending through next decade

By Holly Campbell  |    April 16, 2020
National Health Expenditure (NHE) data projections recently released by the Centers for Medicare & Medicaid Services (CMS) indicate retail medicine spending grew 3.2% in 2019 and will continue to...   Read More

Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines

By Stephen J. Ubl  |    April 15, 2020
As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have created programs empowering employees with medical or laboratory expertise to...   Read More

Guest post: Securing the health care supply chain during COVID-19

By Guest Contributor  |    April 14, 2020
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

To the millions affected by COVID-19

By Stephen J. Ubl and Giovanni Caforio, M.D.  |    April 9, 2020
In these unprecedented times, it can be hard to feel optimistic, but there are reasons to stay positive. The Food and Drug Administration has expedited approval of diagnostic tests. Hospitals and...   Read More

New infographic: How we are fighting COVID-19

By Tom Wilbur  |    April 8, 2020
America’s biopharmaceutical companies have joined forces to fight COVID-19. Armed with experience garnered from previous outbreaks and a vast storehouse of knowledge about infectious diseases like...   Read More

PhRMA submits comments on CMS’s Part D specialty tier proposal

By Tom Wilbur  |    April 7, 2020
Yesterday, PhRMA submitted comments on a Centers for Medicare & Medicaid Services (CMS) proposed rule on policy and technical changes to Medicare Part D and Medicare Advantage.   Read More

Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19

By Andrew Powaleny  |    April 6, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for...   Read More

The biopharmaceutical industry’s unique role in responding to COVID-19

By Richard Moscicki, M.D.  |    April 2, 2020
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock...   Read More

ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus

By Gabby Migliara  |    April 1, 2020
Recently, PhRMA hosted a teleconference to provide an update on our member companies’ around-the-clock efforts in developing treatments and vaccines for COVID-19, a disease caused by a novel...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates